| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NET |
| Uniprot No | P41970 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-407aa |
| 氨基酸序列 | MESAITLWQFLLQLLLDQKHEHLICWTSNDGEFKLLKAEEVAKLWGLRKNKTNMNYDKLSRALRYYYDKNIIKKVIGQKFVYKFVSFPEILKMDPHAVEISRESLLLQDSDCKASPEGREAHKHGLAALRSTSRNEYIHSGLYSSFTINSLQNPPDAFKAIKTEKLEEPPEDSPPVEEVRTVIRFVTNKTDKHVTRPVVSLPSTSEAAAASAFLASSVSAKISSLMLPNAASISSASPFSSRSPSLSPNSPLPSEHRSLFLEAACHDSDSLEPLNLSSGSKTKSPSLPPKAKKPKGLEISAPPLVLSGTDIGSIALNSPALPSGSLTPAFFTAQTPNGLLLTPSPLLSSIHFWSSLSPVAPLSPARLQGPSTLFQFPTLLNGHMPVPIPSLDRAASPVLLSSNSQKS |
| 预测分子量 | 44,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NET(Neutrophil Extracellular Traps)重组蛋白的3篇参考文献，包含文献名称、作者及摘要要点：
---
1. **文献名称**: *"Recombinant HMGB1 induces neutrophil extracellular trap formation in a TLR4-dependent manner"*
**作者**: Yang H et al.
**摘要**: 研究通过重组HMGB1蛋白激活中性粒细胞，证明其通过TLR4信号通路促进NETs释放，揭示了HMGB1在炎症性疾病中调控NETosis的机制。
2. **文献名称**: *"Recombinant peptidylarginine deiminase 4 promotes neutrophil extracellular trap formation in vitro"*
**作者**: Lewis HD et al.
**摘要**: 利用重组PAD4蛋白，证明其催化组蛋白瓜氨酸化是NET形成的必要条件，为自身免疫疾病中靶向PAD4的治疗策略提供依据。
3. **文献名称**: *"Recombinant DNase I suppresses neutrophil extracellular traps and reduces ischemic brain injury in mice"*
**作者**: Kimball AS et al.
**摘要**: 通过重组DNase I降解NETs中的DNA骨架，显著减轻小鼠脑缺血再灌注损伤，提示重组酶在NETs相关病理中的治疗潜力。
---
以上研究聚焦重组蛋白在NET形成、调控及治疗中的应用，涵盖炎症、自身免疫及缺血性疾病模型。如需更多文献或具体领域，可进一步补充关键词细化检索。
**Background of NET Recombinant Proteins**
Neutrophil extracellular traps (NETs) are web-like structures released by neutrophils during a process called NETosis. These structures consist of DNA, histones, and antimicrobial proteins, playing a dual role in host defense and inflammation. Dysregulated NET formation is linked to autoimmune diseases (e.g., rheumatoid arthritis), thrombosis, and cancer metastasis. To study NET-related mechanisms and therapeutic strategies, researchers utilize recombinant proteins mimicking NET components or regulators.
NET recombinant proteins are engineered using biotechnological platforms (e.g., *E. coli*, mammalian cells) to express specific NET-associated molecules, such as myeloperoxidase (MPO), neutrophil elastase (NE), or peptidylarginine deiminase 4 (PAD4). These proteins enable precise investigation of NETosis pathways, protein-DNA interactions, and immune responses. For instance, recombinant PAD4 facilitates studies on histone citrullination, a key step in NET formation, while recombinant NE helps explore protease-driven tissue damage in inflammatory diseases.
Applications span basic research, drug discovery, and diagnostics. Recombinant NET proteins are used to screen inhibitors targeting NETosis (e.g., PAD4 inhibitors for autoimmune disorders) or to develop assays detecting NET biomarkers in patient sera. They also aid in producing antibodies for therapeutic or diagnostic purposes. Challenges include maintaining post-translational modifications (critical for function) and scaling production without compromising stability. Advances in expression systems and purification techniques continue to enhance their reliability and accessibility, driving innovation in understanding NET biology and related therapeutics.
×
